Vivione Biosciences Inc. and Kirkegaard & Perry Laboratories, Inc. Announce New Collaboration

/NOT FOR DISTRIBUTION TO UNITED STATES WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/

CALGARY, Aug. 13, 2013 /CNW/ - Vivione Biosciences Inc. ("Vivione") (TSXV: VBI) is pleased to announce a new development relationship with Kirkegaard & Perry Laboratories, Inc. ("KPL"). This relationship is expected to allow Vivione to accelerate commercialization of the detection kits used in Vivione's RAPID-B food-borne pathogen detection platform. The detection kits will be powered by KPL's well-characterized BacTrace^® affinity-purified primary antibodies. Vivione and KPL plan immediate initiation of manufacturing and commercialization of the detection kits, with the first commercial detection kit (E. coli O157:H7) already submitted for independent certification by the Association of Analytical Communities.

Vivione's RAPID-B system combines flow cytometry with proprietary reagents (contained in detection kits which are designed to target a particular pathogen) and has the potential to provide food pathogen detection down to a single cell in as little as seven hours (including sample preparation) versus up to 48 hours for competing culture based methods. The resulting system offers much higher performance compared to other rapid diagnostic systems currently on the market. Unlike culture-based methods, the RAPID-B system does not require isolation of bacteria and works with background interference from complex matrices like food.

The RAPID-B system is easy to operate by lab personnel and does not require frequent calibration like most flow cytometer systems, making the RAPID-B system more capable of being used in real manufacturing environments. Bacteria detection, data collection, and analysis are seamless with results being provided after only 60 seconds in the system (which does not include sample preparation).

"Vivione collaborated with the U.S. Food and Drug Administration's National Center for Toxicological Research (NCTR) over the past 6 years to accomplish the development and testing of the RAPID-B system," said Kevin Kuykendall, Chief Executive Officer of Vivione. "The strategic relationship with KPL enables us to immediately expand our product offerings and get to market much faster by leveraging their leadership expertise in antibody-based reagent production."

For more than 20 years, KPL has been a well-recognized leader in high specificity, polyclonal, affinity-purified antibodies for food-borne pathogen detection. Although most interest today lies in KPL's offering of antibodies for Salmonella, STECs, E. coli O157:H7, Listeria, and Campylobacter, KPL has a continuous stream of new products in development to detect infectious disease and emerging food-borne pathogens that Vivione will be able to leverage going forward.

Albert Perry, Chief Executive Officer of KPL stated, "The Vivione relationship is a perfect example of what we do best. A significant portion of our business success stems from enabling our supply partners to accelerate commercialization with products that we are confident are robust and work the same way year after year.  We are pleased to be part of the RAPID-B commercialization program and believe it will provide food manufacturers with the ability to reduce their time to results while providing more accurate information which can be used to reduce potential recalls and provide better consumer protection."

About Vivione

Vivione's business is centered on the commercialization of the RAPID-B system, which is an integrated system of hardware, software and chemical reagents that tests bacteria in key environments. This technology could have potentially diverse applicability from food safety to clinical diagnostics, by identifying and quantifying microorganism levels more rapidly and with greater precision than currently employed techniques.

About KPL

Founded in 1979, KPL was the first company to commercialize affinity purified secondary antibodies, a valuable tool for biological research and in vitro diagnostic testing. Since then KPL has introduced more than 850 reagents and complete assay kits for protein visualization that address the needs of life science researchers. Many leading diagnostic kit manufacturers utilize KPL reagents in a variety of commercially successful diagnostic kits for AIDS, tropical diseases, food testing, and cancer. KPL supports it customers by providing individualized attention, technical service, and customer orders.

Cautionary Statements

This news release contains "forward-looking statements" within the meaning of applicable securities laws. Although Vivione believes that the expectations reflected in its forward-looking statements are reasonable, such statements have been based on factors and assumptions concerning future events that may prove to be inaccurate. These factors and assumptions are based upon currently available information to Vivione. Such statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. In particular, this press release contains forward-looking information relating to the commercialization and anticipated effectiveness of RAPID-B and the anticipated benefits from Vivione's relationship with KPL. Readers are cautioned to not place undue reliance on forward-looking statements. The statements in this press release are made as of the date of this release and, except as required by applicable law, Vivione does not undertake any obligation to publicly update or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise. Vivione undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of Vivione, or its financial or operating results or (as applicable), their securities.

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

SOURCE: Vivione Biosciences Inc.

Vivione Biosciences Inc.      
Kevin Kuykendall
Chief Executive Officer
Tel: [phone]